NorthCrest Asset Manangement’s BioMarin Pharmaceuticals BMRN Stock Holding History

NorthCrest Asset Manangement’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$478K	Sell	7,974 -2,752	-26%	-$151K	0.01%	579
2026 Q1	$595K	Sell	10,726 -1,757	-14%	-$102K	0.02%	428
2025 Q4	$735K	Buy	12,483 +564	+5%	+$30.7K	0.02%	435
2025 Q3	$652K	Buy	11,919 +8,412	+240%	+$481K	0.02%	423
2025 Q2	$202K	Sell	3,507 -1,378	-28%	-$81.1K	0.01%	605
2025 Q1	$345K	Buy	+4,885	New	+$329K	0.01%	487

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

NorthCrest Asset Manangement's BMRN Position: Q2 2026 in Review

NorthCrest Asset Manangement reduced its BioMarin Pharmaceuticals (BMRN) stake by 26% in Q2 2026, selling an estimated $151K and leaving 7,974 shares worth $478K. The position accounts for 0.01% of the portfolio, ranked #579.

NorthCrest Asset Manangement first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $735K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

NorthCrest Asset Manangement held 7,974 shares of BioMarin Pharmaceuticals worth $478K as of Q2 2026.
NorthCrest Asset Manangement sold 2,752 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $151K.
BioMarin Pharmaceuticals made up 0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #579 holding.
NorthCrest Asset Manangement first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
NorthCrest Asset Manangement's BioMarin Pharmaceuticals position peaked at $735K in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.